In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company would acquire the Advanced Bioprocessing Business from Becton Dickinson (BDX).
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.
Thermo Fisher Scientific offers products including analytical instruments, reagents, equipment, and consumables, diagnostics and research software, and services.
On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of the new Thermo Scientific Chromeleon XTR Laboratory Management system, which was designed to manage an entire laboratory.
Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]
Becton Dickinson (BDX) announced its fiscal 2018 guidance, which includes the company’s recently acquired Bard business, during the company’s 1Q18 earnings release.
Thermo Fisher Scientific (TMO) will announce its 4Q17 and fiscal 2017 results on January 31, 2018. It has launched some innovative products and entered into strategic collaborations and partnerships.
Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), and T2 Biosystems (TTOO).
Stryker (SYK) offers products across its three business segments: Orthopedics, MedSurg, and Neurotechnology and Spine. The company reported strong performance across all of its business segments in fiscal 3Q17.
Earnings results Baxter International (BAX) is expected to announce its 4Q17 and fiscal 2017 earnings results on or around January 30, 2018. The company announced stellar 3Q17 earnings results on October 25, 2017. Year-over-year, Baxter International expects to report 4Q17 sales growth of 4%–5% and constant-currency sales growth of ~2%. However, the company’s operational sales growth, expected […]
Analysts’ recommendations Baxter International (BAX), one of the United States’ leading medical technology companies, offers renal and hospital solutions to healthcare providers. The company has witnessed strong growth momentum recently, and Wall Street has grown increasingly bullish on the company’s growth prospects. In this article, we’ll look at analysts’ recent recommendations, ratings, and price targets for BAX stock. […]
On December 28, Becton, Dickinson and Company (BDX), or BD, closed trading on the day at $214.32 per share. Currently, BD stock’s 50-day moving average stands at $221.22.
On December 4, 2017, Leerink Swann reaffirmed its “outperform” rating on Thermo Fisher Scientific (TMO). It decreased its target price on TMO stock from $216.00 per share to $200.00 per share.
On December 4, 2017, Leerink Swan reiterated its “overweight” rating on TMO stock. The investment research firm has a 12-month target price of $200.00 per share on the stock.
On December 4, 2017, Thermo Fisher Scientific (TMO) completed the acquisition of some assets from EPTEK Technology and related entities that have offices in mainland China and Taiwan.
On December 7, 2017, Thermo Fisher Scientific (TMO) announced that its Oncomine Dx Target Test had been proposed for coverage by the CMS (Centers for Medicare & Medicaid Services).
Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities.
In December 2017, Thermo Fisher Scientific (TMO) expanded its partnership with Genome Diagnostics (or GenDx), a Netherlands-based firm offering molecular diagnostics solutions.
Overview Stryker (SYK), a leading medical technology company in the United States, has a wide portfolio of products across its three business segments: Orthopaedics, MedSurg, and NeuroTech and Spine. The company has witnessed tremendous growth over the past few years. It registered strong earnings in fiscal 3Q17 and has exceeded analysts’ estimates for the past several quarters. […]
Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.
Overview BD (BDX) has registered strong operating margin expansion in recent years. Its margin improved by 100 basis points in fiscal 2015 and 200 basis points in fiscal 2016. In fiscal 2017, BD’s margin expanded by ~180 basis points. In 4Q17, BD’s operating margin grew ~14.6% YoY (year-over-year), limited by 700 basis points due to the divestiture of BD’s […]
On October 3, 2017, Abbott announced the completion of its acquisition of Alere, which has had troubles since the initial announcement in February 2016.
Abbott (ABT) registered sales growth of ~5% in its Diagnostics business in 3Q17. The segment’s sales were driven by a strong performance outside the US.
Abbott registered strong 3Q17 results, surpassing estimates for both sales and earnings and reporting healthy growth across all of its business segments.
Deal overview On October 24, 2017, Stryker (SYK) acquired the majority share capital of Vexim. The acquisition of a controlling stake in Vexim has provided Stryker with an expanded portfolio of minimally invasive technologies. SYK stock fell ~0.15% that day. The Vanguard S&P 500 ETF (VOO), which has a ~0.22% exposure to Stryker, fell ~0.23%. Following the […]
BSX’s EPS estimate for 3Q17 represents YoY (year-over-year) growth in the range of 9%–16%. In 2Q17, Boston Scientific registered EPS growth of 18.5% YoY.
BD has a strong product pipeline of innovative products under development in its LifeSciences segment, which includes the company’s diagnostic offerings.
Becton Dickinson accelerated its strategy to establish itself as the leader in single cell genomics with its recent launch of BD Rhapsody, a single cell analysis platform.
Abbott Laboratories (ABT) released its 2Q17 earnings results on July 20, 2017, reporting strong results for revenues as well as earnings and exceeding Wall Street’s estimates.
On August 31, Stryker (SYK) closed trading at a closing price of $139.3. It has a 50-day moving average of $144.7 and a 200-day moving average of $137.5.
On June 29, 2017, Thermo Fisher Scientific (TMO) announced the addition of three new products to its semiconductor failure analysis workflows portfolio.
In a recent Reuters survey of 17 brokerage companies, Thermo Fisher Scientific received “buy” ratings from ~88% of analysts, while ~12% gave it “hold” ratings.
